Evaluation of Second-Line Treatment for Castration-Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors
This study evaluated the effects of docetaxel and androgen receptor signaling inhibitors as second-line treatments in patients with castration-resistant prostate cancer after androgen receptor signaling inhibitors as first-line treatment. This study retrospectively evaluated the clinical outcomes of...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Prostate Cancer |
| Online Access: | http://dx.doi.org/10.1155/2024/9303603 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841564290627141632 |
|---|---|
| author | Kazuro Kikkawa Masahiro Tamaki Kouhei Maruno Tatsuya Hazama Toshifumi Takahashi Yuya Yamada Masakazu Nakashima Noriyuki Ito |
| author_facet | Kazuro Kikkawa Masahiro Tamaki Kouhei Maruno Tatsuya Hazama Toshifumi Takahashi Yuya Yamada Masakazu Nakashima Noriyuki Ito |
| author_sort | Kazuro Kikkawa |
| collection | DOAJ |
| description | This study evaluated the effects of docetaxel and androgen receptor signaling inhibitors as second-line treatments in patients with castration-resistant prostate cancer after androgen receptor signaling inhibitors as first-line treatment. This study retrospectively evaluated the clinical outcomes of second-line treatment with docetaxel or androgen receptor signaling inhibitor in patients with castration-resistant prostate cancer who received first-line treatment with androgen receptor signaling inhibitors. Clinical backgrounds and outcomes were compared between docetaxel and androgen receptor signaling inhibitors as second-line treatment. Of 59 patients, 21 (35.6%) and 38 (64.4%) received docetaxel and androgen receptor signaling inhibitors as second-line treatment after first-line treatment with androgen receptor signaling inhibitors, respectively. In the second-line setting, the median progression-free survival was longer with androgen receptor signaling inhibitor than with docetaxel (17 versus 6 months, P=0.014). In the first-line setting, the median progression-free survival was longer with androgen receptor signaling inhibitors than with docetaxel (32 versus 25 months, P=0.014); however, no significant difference was found in the overall survival. Multivariate analysis revealed that there was no significant association between second-line treatment and survival, and first-line treatment with abiraterone was identified as a prognostic factor for progression-free survival. Subgroup analysis showed that the abiraterone–enzalutamide sequence was more effective than the other three sequences for progression-free survival and overall survival. This study suggests that second-line treatment with an androgen receptor signaling inhibitor for castration-resistant prostate cancer after androgen receptor signaling inhibitors as first-line treatment may be more beneficial, particularly with abiraterone as the upfront treatment. |
| format | Article |
| id | doaj-art-0726bb991dbc4a29a3ace380048d7958 |
| institution | Kabale University |
| issn | 2090-312X |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Prostate Cancer |
| spelling | doaj-art-0726bb991dbc4a29a3ace380048d79582025-01-02T22:52:39ZengWileyProstate Cancer2090-312X2024-01-01202410.1155/2024/9303603Evaluation of Second-Line Treatment for Castration-Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling InhibitorsKazuro Kikkawa0Masahiro Tamaki1Kouhei Maruno2Tatsuya Hazama3Toshifumi Takahashi4Yuya Yamada5Masakazu Nakashima6Noriyuki Ito7Department of UrologyDepartment of UrologyDepartment of UrologyDepartment of UrologyDepartment of UrologyDepartment of UrologyDepartment of UrologyDepartment of UrologyThis study evaluated the effects of docetaxel and androgen receptor signaling inhibitors as second-line treatments in patients with castration-resistant prostate cancer after androgen receptor signaling inhibitors as first-line treatment. This study retrospectively evaluated the clinical outcomes of second-line treatment with docetaxel or androgen receptor signaling inhibitor in patients with castration-resistant prostate cancer who received first-line treatment with androgen receptor signaling inhibitors. Clinical backgrounds and outcomes were compared between docetaxel and androgen receptor signaling inhibitors as second-line treatment. Of 59 patients, 21 (35.6%) and 38 (64.4%) received docetaxel and androgen receptor signaling inhibitors as second-line treatment after first-line treatment with androgen receptor signaling inhibitors, respectively. In the second-line setting, the median progression-free survival was longer with androgen receptor signaling inhibitor than with docetaxel (17 versus 6 months, P=0.014). In the first-line setting, the median progression-free survival was longer with androgen receptor signaling inhibitors than with docetaxel (32 versus 25 months, P=0.014); however, no significant difference was found in the overall survival. Multivariate analysis revealed that there was no significant association between second-line treatment and survival, and first-line treatment with abiraterone was identified as a prognostic factor for progression-free survival. Subgroup analysis showed that the abiraterone–enzalutamide sequence was more effective than the other three sequences for progression-free survival and overall survival. This study suggests that second-line treatment with an androgen receptor signaling inhibitor for castration-resistant prostate cancer after androgen receptor signaling inhibitors as first-line treatment may be more beneficial, particularly with abiraterone as the upfront treatment.http://dx.doi.org/10.1155/2024/9303603 |
| spellingShingle | Kazuro Kikkawa Masahiro Tamaki Kouhei Maruno Tatsuya Hazama Toshifumi Takahashi Yuya Yamada Masakazu Nakashima Noriyuki Ito Evaluation of Second-Line Treatment for Castration-Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors Prostate Cancer |
| title | Evaluation of Second-Line Treatment for Castration-Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors |
| title_full | Evaluation of Second-Line Treatment for Castration-Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors |
| title_fullStr | Evaluation of Second-Line Treatment for Castration-Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors |
| title_full_unstemmed | Evaluation of Second-Line Treatment for Castration-Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors |
| title_short | Evaluation of Second-Line Treatment for Castration-Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors |
| title_sort | evaluation of second line treatment for castration resistant prostate cancer following the administration of upfront androgen receptor signaling inhibitors |
| url | http://dx.doi.org/10.1155/2024/9303603 |
| work_keys_str_mv | AT kazurokikkawa evaluationofsecondlinetreatmentforcastrationresistantprostatecancerfollowingtheadministrationofupfrontandrogenreceptorsignalinginhibitors AT masahirotamaki evaluationofsecondlinetreatmentforcastrationresistantprostatecancerfollowingtheadministrationofupfrontandrogenreceptorsignalinginhibitors AT kouheimaruno evaluationofsecondlinetreatmentforcastrationresistantprostatecancerfollowingtheadministrationofupfrontandrogenreceptorsignalinginhibitors AT tatsuyahazama evaluationofsecondlinetreatmentforcastrationresistantprostatecancerfollowingtheadministrationofupfrontandrogenreceptorsignalinginhibitors AT toshifumitakahashi evaluationofsecondlinetreatmentforcastrationresistantprostatecancerfollowingtheadministrationofupfrontandrogenreceptorsignalinginhibitors AT yuyayamada evaluationofsecondlinetreatmentforcastrationresistantprostatecancerfollowingtheadministrationofupfrontandrogenreceptorsignalinginhibitors AT masakazunakashima evaluationofsecondlinetreatmentforcastrationresistantprostatecancerfollowingtheadministrationofupfrontandrogenreceptorsignalinginhibitors AT noriyukiito evaluationofsecondlinetreatmentforcastrationresistantprostatecancerfollowingtheadministrationofupfrontandrogenreceptorsignalinginhibitors |